REG - AstraZeneca PLC - Additional financial information-Grünenthal deal

AstraZenecaAnnouncement

31/10/2018 09:45

RNS Number : 8517F
AstraZeneca PLC
31 October 2018
 


31 October 2018 09:45 GMT
Additional financial information in respect of the previously-

announced agreement with Grünenthal for rights to

Nexium in Europe and Vimovo worldwide (ex-US)
Pursuant to Listing Rule 10.4.1R (notification of class 2 transactions), AstraZeneca provides the following additional financial information in respect of the previously-announced agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US). The announcement of the agreement was initially released at 07:00 GMT on 30 October 2018.
The book value of gross assets subject to the divestments was approximately $99 million at 31 December 2017. In the year to 31 December 2017 the aggregate pre-tax profits attributable to Nexium and Vimovo in the relevant territories were $203 million. The consideration will be satisfied in cash and the proceeds used for general corporate purposes.
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.



Media Relations












Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jennifer Hursit


UK/Global


+44 203 749 5762




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677


















Investor Relations












Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


Cardiovascular; Metabolism


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




Josie Afolabi


Other


+44 203 749 5631




Craig Marks


Finance; Fixed Income


+44 7881 615 764




Jennifer Kretzmann


Retail Investors


+44 203 749 5824




US toll-free






+1 866 381 7277



 
Adrian Kemp
Company Secretary
AstraZeneca PLC




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFDUSUFFASEDS